Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

被引:375
作者
Bengtsson, AA [1 ]
Sturfelt, G
Truedsson, L
Blomberg, J
Alm, G
Vallin, H
Rönnblom, L
机构
[1] Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden
[2] Univ Lund Hosp, Dept Clin Microbiol, S-22185 Lund, Sweden
[3] Univ Hosp, Dept Clin Microbiol, Sect Virol, Uppsala, Sweden
[4] Swedish Univ Agr Sci, Dept Vet Microbiol, Immunol Sect, Uppsala, Sweden
[5] Uppsala Univ, Dept Med Sci, Rheumatol Sect, Uppsala, Sweden
关键词
SLE; interferon-alpha; retrovirus; SLEDAI; interferon inducer;
D O I
10.1191/096120300674499064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective was to investigate the relation between serum levels of interferon-alpha (IFN-alpha), the activity of an endogenous IFN-alpha inducing factor (SLE-IIF), clinical and immunological disease activity as well as serum levels of antiretroviral antibodies in SLE. Serum levels of IFN-alpha were measured in serial sera from 30 patients sampled at different stages of disease activity (SLEDAI score). The SLE-IIF activity was measured by its ability to induce IFN-alpha production in cultures of normal peripheral blood mononuclear cells. Both serum IFN-alpha and SLE-IIF increased markedly at flare in serially followed patients. The SLEDAI score, levels of anti-dsDNA antibodies and IL-10 correlated positively, and complement components Clq, C3 and leukocytes correlated inversely with serum concentrations of IFN-alpha. The extent of multiple organ involvement correlated with serum IFN-alpha. No relation between concentrations of retroviral peptide binding antibodies and IFN-alpha or SLE-IIF activity was found. The close relationship between disease activity in SLE patients and IFN-alpha serum levels suggests that activation of the type I IFN system might be of importance in the disease process.
引用
收藏
页码:664 / 671
页数:8
相关论文
共 49 条
[1]   Interferon-alpha stimulates production of interleukin-10 in activated CD4(+) T cells and monocytes [J].
Aman, MJ ;
Tretter, T ;
Eisenbeis, I ;
Bug, G ;
Decker, T ;
Aulitzky, WE ;
Tilg, H ;
Huber, C ;
Peschel, C .
BLOOD, 1996, 87 (11) :4731-4736
[2]   ROLE OF INTERFERONS AND OTHER CYTOKINES IN THE REGULATION OF THE IMMUNE-RESPONSE [J].
BELARDELLI, F .
APMIS, 1995, 103 (03) :161-179
[3]   Selective antibody reactivity with peptides from human endogenous retroviruses and nonviral poly(amino acids) in patients with systemic lupus erythematosus [J].
Bengtsson, A ;
Blomberg, J ;
Nived, O ;
Pipkorn, R ;
Toth, L ;
Sturfelt, G .
ARTHRITIS AND RHEUMATISM, 1996, 39 (10) :1654-1663
[4]   DNA levels in circulating immune complexes decrease at severe SLE flares - Correlation with complement component C1q [J].
Bengtsson, A ;
Nezlin, R ;
Shoenfeld, Y ;
Sturfelt, G .
JOURNAL OF AUTOIMMUNITY, 1999, 13 (01) :111-119
[5]   Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections [J].
Biron, CA .
SEMINARS IN IMMUNOLOGY, 1998, 10 (05) :383-390
[6]   INCREASED ANTIRETROVIRAL ANTIBODY REACTIVITY IN SERA FROM A DEFINED POPULATION OF PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - CORRELATION WITH AUTOANTIBODIES AND CLINICAL MANIFESTATIONS [J].
BLOMBERG, J ;
NIVED, O ;
PIPKORN, R ;
BENGTSSON, A ;
ERLINGE, D ;
STURFELT, G .
ARTHRITIS AND RHEUMATISM, 1994, 37 (01) :57-66
[7]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[8]   Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells [J].
Cederblad, B ;
Blomberg, S ;
Vallin, H ;
Perers, A ;
Alm, GV ;
Ronnblom, L .
JOURNAL OF AUTOIMMUNITY, 1998, 11 (05) :465-470
[9]   DEFICIENT HERPES-SIMPLEX VIRUS-INDUCED INTERFERON-ALPHA PRODUCTION BY BLOOD LEUKOCYTES OF PRETERM AND TERM NEWBORN-INFANTS [J].
CEDERBLAD, B ;
RIESENFELD, T ;
ALM, GV .
PEDIATRIC RESEARCH, 1990, 27 (01) :7-10
[10]  
Chakrabarti D, 1996, J IMMUNOL, V157, P522